A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Bioavailability and Food Effect of Various Oral Formulations of a Novel Investigational Compound in Healthy Volunteers

The primary objective of this study is to evaluate the bioequivalence of different formulations of a new medicinal product. This assessment is clinically significant to ensure consistent bioavailability and therapeutic performance across various delivery methods. Secondary objectives include the investigation of the food effect on the absorption profiles of the medication within healthy participants.

The sponsor did not provide information regarding the total number of participants. The study population consists of healthy volunteers of both male and female genders. Participants fall within the age range categorized by code 3. The study population is characterized by the absence of psoriasis.

This Phase 3 clinical trial utilizes a randomized, controlled study design to evaluate the bioavailability of various formulations of a new medicinal product. The research aims to compare drug absorption rates across different formulations and assess the impact of food intake on these processes in healthy participants. The study sequence begins with a screening visit to determine eligibility. Following screening, participants proceed through scheduled study visits designed to monitor physiological responses and data collection. The protocol concludes with an end-of-study visit. The total duration of participant involvement is determined by the specific procedural timeline. Early termination from the study may occur based on predefined clinical criteria or safety protocols.

Efficacy assessment for Psoriasis in this Phase 3 clinical trial will be conducted according to the established protocol. Specific parameters, methods, and schedules for evaluating therapeutic response are not detailed in the provided source material.